样式: 排序: IF: - GO 导出 标记为已读
-
Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-19 Ann Oluloro, Elizabeth M Swisher, Heidi J Gray, Barbara Goff, Kemi M Doll
Background Racial and ethnic minorities remain underrepresented in gynecologic cancer clinical trials despite disproportionately worse oncologic outcomes. Research shows differential racial enrollment patterns due to comorbidity-based exclusion criteria (CEC). Our objective was to evaluate contemporary trends in CECs among NCI-sponsored gynecologic cancer clinical trials and protocol adherence to broadened
-
Reducing-a little-the high price of randomized trials of the efficacy of multicancer early detection. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-19 Noel S Weiss
-
Testing stored control-arm specimens could dramatically increase statistical power yet reduce costs in cancer screening trials. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-19 Hormuzd A Katki
-
The widespread application of trans-oral robotic surgery in HPV-related head and neck cancer: one size does not fit all. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-19 Mihir R Patel,Barbara Burtness,Robert L Ferris,Nabil F Saba
-
Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-17 Xinyi Li, Jinhee Hur, Yin Zhang, Mingyang Song, Stephanie A Smith-Warner, Liming Liang, Kenneth J Mukamal, Eric B Rimm, Edward L Giovannucci
Background Association between light to moderate alcohol consumption and colorectal cancer (CRC) incidence remains understudied, especially regarding drinking pattern, beverage type and temporal aspects. Methods Hazard ratios (HRs) and 95% confidence intervals (CIs) for time to CRC diagnosis were estimated among 137,710 participants. Estimates based on remote (eg, >10 years before follow-up) and recent
-
TP53 missense allele predisposing to high risk of breast cancer but not pediatric cancers J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-14 Suhair Lolas-Hamameh, Sari Lieberman, Alaa Sarahneh, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Grace Rabie, Rachel Beeri, Amal Aburayyan, Jessica B Mandell, Hila Fridman, Galit Lazer-Derbeko, Tehila Klopstock, Orit Freireich, Amnon Lahad, Mary-Claire King, Ephrat Levy-Lahad, Moien N Kanaan
Pathogenic TP53 germline variants cause young-onset breast cancer and other cancers of the Li-Fraumeni syndrome (LFS) spectrum, but the clinical consequences of partial-loss-of function TP53 variants are incompletely understood. In the consecutive cohort of Palestinian breast cancer patients of the Middle East Breast Cancer Study (MEBCS), breast cancer risk among TP53 p. R181C heterozygotes was 50%
-
Acceptability of an organ inventory for cancer screening across gender identity and intersex status J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-14 Heidi Moseson, Sachiko Ragosta, Anu Manchikanti Gómez, Jae Corman, Jay Zussman, Bori Lesser-Lee, Sydney Reese, India Rose Carter-Bolick, Juno Obedin-Maliver
Objectives To evaluate the acceptability and performance of an organ inventory as an alternative to asking about gender and/or sex assigned at birth in cancer screening. Methods We fielded an online, self-administered survey to a convenience sample of English- or Spanish-speaking transgender and gender-diverse (TGD), intersex, and cisgender people (>/=15 years) in the US. The survey contained an organ
-
Evaluating the performance of the BOADICEA model in predicting 10-year breast cancer risks in UK Biobank J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-12 Carmen Petitjean, Naomi Wilcox, Lorenzo Ficorella, Joe Dennis, Jonathan Tyrer, Michael Lush, Jacques Simard, Douglas Easton, Antonis C Antoniou, Xin Yang
Background The BOADICEA model predicts breast cancer risk using cancer family history, epidemiological and genetic data. We evaluated its validity in a large prospective cohort. Methods We assessed model calibration, discrimination and risk classification ability in 217,885 women (6,838 incident breast cancers) aged 40-70 years old of self-reported White ethnicity with no previous cancer from the UK
-
Time-Restricted Eating and Cancer: Lessons Learned and Considerations for a Path Forward J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-12 Marissa M Shams-White, Audrey A Goldbaum, Tanya Agurs-Collins, Susan Czajkowski, Kirsten A Herrick, Linda Nebeling, Jill Reedy, Gabriela Riscuta, Sharon Ross, Edward R Sauter
Time-restricted eating (TRE) is a type of intermittent fasting (IF). Food can be consumed as desired during the eating period, but not during the remainder of the day. Studies suggest that many of the health benefits of fasting may not simply be the result of weight loss, but also due to the body’s responses to the fasting that lead to improved metabolic functioning. While animal studies are convincing
-
Optimizing public-private partnerships to support clinical cancer research J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-11 Roy S Herbst, Gideon Blumenthal, Samir N Khleif, Scott M Lippman, Neal J Meropol, Kristen Rosati, Lawrence N Shulman, Heind Smith, Meina Wang, Robert A Winn, Richard L Schilsky
Public-private partnerships (PPPs) in cancer research have emerged as a pivotal model in the development of strategies to rapidly advance therapeutic innovations. The collaboration between public entities, such as government agencies and research institutions, and private entities, including pharmaceutical and biotechnology companies, as well as nonprofit organizations, brings together diverse expertise
-
Impact of radiotherapy dose, fractionation and immunotherapeutic partner in a mouse model of HR+ mammary carcinogenesis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-11 Aitziber Buqué, Norma Bloy, Giulia Petroni, Carlos Jiménez-Cortegana, Ai Sato, Cristina Iribarren, Takahiro Yamazaki, Claudia Galassi, Michal Hensler, Bhavneet Bhinder, Andrea Guarracino, Brady Rippon, Manuel Beltran-Visiedo, Ruth Soler-Agesta, Tania Pannellini, Jitka Fucikova, Sandra Demaria, Xi Kathy Zhou, Olivier Elemento, Silvia C Formenti, Lorenzo Galluzzi
Background Hormone receptor (HR)+ breast cancer is poorly responsive to immune checkpoint inhibitors (ICIs). In some settings, radiation therapy (RT) has been shown to mediate immunostimulatory effects and promote ICI sensitivity. Methods We investigated whether hypofractionated RT may be successfully combined with ICIs in a mouse model of multifocal, metachronous HR+ mammary carcinogenesis. We hypothesized
-
Natural history of HPV16-E6 serology among cancer-free men in a multicenter longitudinal cohort study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-11 Jaimie Z Shing, Anna R Giuliano, Nicole L Brenner, Birgitta Michels, Allan Hildesheim, Sudhir Srivastava, Bradley A Sirak, John Schussler, Danping Liu, Wendy Wang, Tim Waterboer, Aimée R Kreimer
Background Human papillomavirus (HPV)16-E6 seropositivity accurately predicts oropharyngeal squamous cell carcinoma (OPSCC) risk decades before diagnosis; but the biomarker’s translational potential is unknown. To inform considerations for OPSCC screening, we described HPV16-E6 seroprevalence, predictors, and kinetics among cancer-free men. Methods In a cohort study in Brazil, Mexico, and United States
-
The role of HPV16 in oral cavity and laryngeal cancers in the United States J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-11 Christine M Kava, Anil K Chaturvedi, Virginia Senkomago, Jacqueline M Mix, Lauri E Markowitz, Aimée R Kreimer, Elizabeth R Unger, Mona Saraiya
In addition to oropharyngeal cancers, evidence suggests there may be an etiologic role for human papillomavirus (HPV) in some other head and neck cancers arising from the oral cavity and larynx. We estimated the burden of HPV16-attributable cancers of the oral cavity (ICD-O-3 site codes C02.0-C02.3, C02.9, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C05.8, C05.9, C06.0-C06.2, C06.8, C06
-
The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045 J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-11 Allini Mafra, Mathieu Laversanne, Rafael Marcos-Gragera, Humberto V S Chaves, Charlene Mcshane, Freddie Bray, Ariana Znaor
Background Multiple myeloma (MM) is an important haematological malignancy in older adults, with a relatively poor prognosis. We aimed to present the current global patterns of incidence and mortality from MM, and predict new cases and deaths by 2045. Methods Estimated numbers of MM cases and deaths and age-standardized (World) incidence and mortality rates per 100,000 people were obtained from the
-
The Evolution of NCI’s Health Information National Trends Survey: Methods, Data, and Future Directions J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-11 Kelly D Blake, Richard P Moser, Heather D’Angelo, Anna Gaysynsky, Robin C Vanderpool
The National Cancer Institute’s (NCI) Health Information National Trends Survey® (HINTS®), was conceived in 1997 during a multidisciplinary conference focused on risk communication that included attendees representing the fields of psychology, health behavior, health education, public health, clinical medicine, and health journalism. The key recommendation from the conference was for NCI to develop
-
HPV genotype-specific prevalence and infection risks: A 10-year population-based study from the United States. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-10 Cosette M Wheeler,Rachael Adcock,William C Hunt,Michael Robertson,Norah E Torrez-Martinez,Ruth McDonald,Emily Merchasin,Steven Jenison,Debbie Saslow,Nancy E Joste,Philip E Castle,Jane J Kim,Jack Cuzick,
BACKGROUND Various studies have reported on the impact of human papillomavirus (HPV) vaccines. Here we present the largest population-based investigation of genotype-specific distributions over the decade following implementation of the 4-valent HPV vaccine (HPV6/11/16/18) in the United States. METHODS Liquid-based cervical cytology samples from individuals aged 15-30 years undergoing cervical screening
-
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-10 Annelie Johansson, Huma Dar, Anna Nordenskjöld, Gizeh Perez-Tenorio, Nicholas P Tobin, Christina Yau, Christopher C Benz, Laura J Esserman, Laura J van ‘t Veer, Bo Nordenskjöld, Olle Stål, Tommy Fornander, Linda S Lindström
Background Estrogen receptor–positive breast cancer patients have a long-term risk of distant metastatic disease, and premenopausal patients have a higher risk. Randomized studies with long-term follow-up are essential to understand treatment benefit. We elucidated the long-term tamoxifen therapy benefit by menopausal status in the Stockholm tamoxifen trials with 20 years complete follow-up. Methods
-
Benchmarks of Success in Radiotherapy versus Systemic Therapy National Clinical Trials Network (NCTN) Randomized Controlled Trials Sponsored by the National Cancer Institute (NCI) J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-10 Nina N Sanford, Qian Shi, David M Hein, William A Hall
Background The National Clinical Trials Network (NCTN) is the largest government sponsored organization in the United States tasked with funding randomized controlled trials (RCTs) in oncology. It is unknown whether there are differences in study design by treatment modality. We evaluated differences in methodology between trials testing radiotherapy versus systemic therapy. Methods The Clinical Trials
-
Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-10 Sofia Palmér, Antonis Valachis, Henrik Lindman, Daniel Robert Smith, Åsa Wickberg, Fredrika Killander, Judith Bjöhle, Zakaria Einbeigi, Greger Nilsson, Johan Ahlgren, Kenneth Villman
Background This prospective cohort study aimed to assess whether postoperative radiotherapy could safely be omitted in women ≥ 65 years with low-risk, estrogen receptor (ER)-positive T1N0 breast cancer treated with breast-conserving surgery and adjuvant endocrine therapy. Methods Eligible patients were women ≥ 65 years with unifocal, non-lobular, grade 1 or 2, ER-positive, pT1N0 breast cancer treated
-
Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-10 Troy J Kleber, Alexander D Sherry, Andrew J Arifin, Gabrielle S Kupferman, Ramez Kouzy, Joseph Abi Jaoude, Timothy A Lin, Esther J Beck, Avital M Miller, Adina H Passy, Zachary R Mccaw, Pavlos Msaouel, Ethan B Ludmir
Background Noninferiority (NI) and equivalence trials evaluate whether an experimental therapy’s effect on the primary endpoint (PEP) is contained within an acceptable margin compared to standard-of-care. The reliability and impact of this conclusion, however, is largely dependent on the justification for this design, the choice of margin, and the analysis population used. Methods A meta-epidemiological
-
Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-10 Yara Abdou, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Daniel F Hayes, Nancy U Lin, Edith A Perez, Lori J Goldstein, Stephen K L Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Anne F Schott, Steven Shak, Priyanka Sharma, Danika L Lew, Jieling Miao, Joseph M Unger, Debasish Tripathy, Gabriel N Hortobagyi, Lajos Pusztai, Kevin Kalinsky
Background The phase III RxPONDER trial has impacted treatment for node-positive(1-3), hormone receptor-positive, HER2-negative breast cancer with 21-gene recurrence score (RS) ≤ 25. We investigated how these findings apply to different racial and ethnic groups within the trial. Methods The trial randomized women to endocrine therapy (ET) or to chemotherapy plus ET. The primary clinical outcome was
-
Editor's Note: Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-09
-
-
Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-03 Jacob B Reibel,Lova L Sun,Ravi B Parikh,Nadim Mahmud,Lainie P Martin,Rebecca A Hubbard,Ronac Mamtani
The recent cisplatin and carboplatin ("platinum") chemotherapy shortage, first announced on February 10, 2023, has impacted cancer patients nationwide. Here, we quantify the extent to which the shortage affected platinum chemotherapy prescribing and short-term mortality. This cohort study included 11 797 adults with advanced solid cancers who initiated first-line therapy during the 1-year period before
-
Increased Occurrence of Malignancy Before and after Chemoradiation for Anal Squamous Cell Carcinoma: A Multi-Institutional Analysis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-03 Ritesh Kumar, Chris L Hallemeier, Daniel T Chang, Shou-En Lu, Lara Hathout, Vasilis C Hristidis, Krishnan R Jethwa, J Richelcyn M Baclay, Veeraswamy Manne, Zakaria Chakrani, Michael G Haddock, Diego Augusto Santos Toesca, Erqi Liu Pollom, Abraham J Wu, Harigopal Sandhyavenu, Paul B Romesser, Salma K Jabbour
Background Anal squamous cell carcinoma (ASCC) is a rare cancer with increased occurrence of multiple cancers before and after the ASCC diagnosis. However, there is limited data on this aspect. This multi-institutional analysis aimed to define the occurrence of malignancies before and after ASCC, time trends, impact on survival, and identify prognostic factors. Material and Methods Initial primary
-
Lung cancer screening with low-dose computed tomography-where do we go from here? J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-01 Ashley Elizabeth Prosper,Yannan Lin,Denise R Aberle
-
New study, same message: association between uninsurance and late-stage cancer diagnosis-time for action. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-29 Cathy J Bradley,Ya-Chen Tina Shih
-
Life after cancer matters: supporting 2.1 million survivors of adolescent and young adult cancer. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-29 AnnaLynn M Williams,Michael E Roth
-
Clinical and patient-reported outcomes after oncoplastic versus conventional breast conserving surgery-a longitudinal, multicenter cohort study. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-29 Claudia A Bargon,Dieuwke R Mink Van Der Molen,Danny A Young-Afat,Marilot C T Batenburg,Iris E Van Dam,Inge O Baas,Miranda F Ernst,Wiesje Maarse,Maartje F Sier,Ernst J P Schoenmaeckers,Josephina P J Burgmans,Rhodé M Bijlsma,Sabine Siesling,Hinne A Rakhorst,Marc Am Mureau,Femke Van Der Leij,Annemiek Doeksen,Helena M Verkooijen,
BACKGROUND Oncoplastic breast conserving surgery (OP-BCS) is becoming increasingly popular to avoid mastectomy or optimize cosmetic outcomes of breast conserving surgery (BCS). Few studies have compared clinical outcomes and patient-reported outcomes (PROs) of OP-BCS to conventional BCS (C-BCS). This study aims to compare clinical outcomes and short and long-term PROs after OP-BCS and C-BCS in a large
-
Gauging the efficacy of multicancer screening: the road ahead may be long and bumpy. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-26 Noel S Weiss
-
Childhood, adolescent and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-25 Shuai Li, Laura Madanat-Harjuoja, Goska Leslie, Daniel R Barnes, Manjeet K Bolla, Joe Dennis, Michael T Parsons, Paraskevi Apostolou, Norbert Arnold, Kristin Bosse, Antonis C Antoniou on behalf of EMBRACE Collaborators, Jackie Cook, Christoph Engel, D Gareth Evans, Florentia Fostira, Megan N Frone, Andrea Gehrig, Mark H Greene, Karl Hackmann, Eric Hahnen, Nadia Harbeck, Jan Hauke, Julia Hentschel,
Background Whether carriers of BRCA1 or BRCA2 (BRCA1/2) pathogenic variants (PVs) have increased risks of childhood, adolescent, and young adult (CAYA) cancers is controversial. We aimed to evaluate this risk and to inform clinical care of young BRCA1/2 PV carriers and genetic testing for CAYA cancer patients. Methods Using data from 47,117 individuals from 3,086 BRCA1/2 families, we conducted pedigree
-
A new age for advance care planning and serious illness conversations in oncology. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-23 Finly Zachariah
-
High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-23 Iris A S Stroot,Joost Bart,Harry Hollema,Marise M Wagner,Refika Yigit,Helena C van Doorn,Joanne A de Hullu,Katja N Gaarenstroom,Marc van Beurden,Luc R C W van Lonkhuijzen,Brigitte F M Slangen,Ronald P Zweemer,Encarna B Gómez Garcia,Margreet G E M Ausems,Fenne L Komdeur,Christi J van Asperen,Muriel A Adank,Marijke R Wevers,Maartje J Hooning,,Marian J E Mourits,Geertruida H de Bock
BACKGROUND Risk-reducing salpingo-oophorectomy (RRSO) effectively prevents high-grade serous carcinoma (HGSC) in BRCA1/2 germline pathogenic variant (GPV) carriers. Still, some women develop HGSC after RRSO without pathologic findings. This study assessed long-term incidence and risk factors for developing HGSC after RRSO without pathologic findings. METHODS BRCA1/2 GPV carriers were selected from
-
Liver Elastography-based Risk Score for Predicting Hepatocellular Carcinoma Risk J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-22 Chan Tian, Chunyan Ye, Haiyan Guo, Kun Lu, Juan Yang, Xiao Wang, Xinyuan Ge, Chengxiao Yu, Jing Lu, Longfeng Jiang, Qun Zhang, Ci Song
Background & Aims Liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE) accurately assesses fibrosis. We aimed to develop a universal risk score for predicting hepatocellular carcinoma (HCC) development in patients with chronic hepatitis. Methods We systematically selected predictors and developed the risk prediction model (HCC-LSM) in the HBV training cohort (n =
-
Trends in cancer mortality under age 50 in 15 upper-Middle and high-income countries J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-22 Claudia Santucci, Silvia Mignozzi, Gianfranco Alicandro, Margherita Pizzato, Matteo Malvezzi, Eva Negri, Prabhat Jha, Carlo La Vecchia
Background Rising cancer incidence, particularly for colorectal cancer, has been reported in young adults. This study examined whether this is related to an increase in mortality. Methods We analysed World Health Organization (WHO) mortality data among young adults aged 25-49 in 15 most populous upper-middle and high-income countries from 1990 to 2021 with reliable data. Mid-year populations were retrieved
-
"Nailing down" risk and improving outcomes in early-stage breast cancer. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-22 Stephanie L Graff,Stacey Tinianov,Kevin Kalinsky
-
Elevated risk of lung cancer among asian American females who have never smoked: an emerging cancer disparity J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-20 Scarlett Lin Gomez, Mindy DeRouen, Moon S Chen, Heather Wakelee, Jeffrey B Velotta, Lori C Sakoda, Salma Shariff-Marco, Peggy Reynolds, Iona Cheng
Lung cancer is a leading cause of cancer mortality for most ethnic groups of Asian American females, including Chinese, Korean, Japanese, and Vietnamese Americans, a striking pattern given the exceedingly low prevalence of smoking among Asian American females in the general population. Recent research demonstrates that among Asian American females diagnosed with lung cancer, the vast majority of patients
-
First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-20 Megan Othus, Sandip P Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon, Razelle Kurzrock
Background Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluated, with most prior research finding a positive association between toxicity and survival. This prior research has generally reported on more common tumor types. We use a unique data resource of a federally-funded basket trial ((NCT02834013) for patients with
-
Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-20 Yibai Zhao, Roman Gulati, Zhenwei Yang, Lisa Newcomb, Yingye Zheng, Kehao Zhu, Menghan Liu, Eveline A M Heijnsdijk, Michael C Haffner, Matthew Cooperberg, Scott E Eggener, Angelo M De Marzo, Adam S Kibel, Dimitris Rizopoulos, Ingrid J Hall, Ruth Etzioni
Background Implications of relabeling grade group (GG) 1 prostate cancer as non-cancer will depend on the recommended active surveillance (AS) strategy. Whether relabeling should prompt de-intensifying, PSA-based active monitoring approaches is unclear. We investigated outcomes of biopsy-based AS strategies vs PSA-based active monitoring for GG1 diagnoses under different patient adherence rates. Methods
-
Proinflammatory Dietary Pattern and Risk of Total and Subtypes of Breast Cancer Among U.S. Women J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-20 Andrea Romanos-Nanclares, Walter C Willett, Bernard Rosner, Daniel G Stover, Sagar D Sardesai, Michelle D Holmes, Wendy Y Chen, Rulla M Tamimi, Fred K Tabung, A Heather Eliassen
Background Dietary patterns promoting chronic inflammation, including the empirical dietary inflammatory pattern (EDIP), have been associated with certain cancers. Investigating whether this dietary pattern is associated with breast cancer—where the role of inflammation is less well-defined—could provide valuable insights and potentially improve strategies for preventing this cancer. Methods We prospectively
-
The Association of Where Patients with Prostate Cancer Live and Receive Care on Racial Treatment Inequities J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-20 Noah Hammarlund, Sarah K Holt, Ruth Etzioni, Danté Morehead, Jenney R Lee, Erika M Wolff, Yohali Burrola-Mendez, Liz Sage, John L Gore, Yaw A Nyame
Black individuals are less likely to be treated for prostate cancer even though they are more than twice as likely to die compared to White individuals. The complex causes of these inequities are influenced by social and structural factors, including racism, which contribute to the differential delivery of care. This study investigates how factors related to the location of where individuals live and
-
Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and Meta-Analysis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-20 Ammar A Javed, Alyssar Habib, Omar Mahmud, Asad Saulat Fatimi, Mahip Grewal, Nabiha Mughal, Jin He, Christopher L Wolfgang, Lois Daamen, Marc G Besselink
Introduction Prognostic markers for overall survival (OS) in resected pancreatic ductal adenocarcinoma (PDAC) are well-established but remain unclear following neoadjuvant therapy (NAT). This systematic review and meta-analysis aimed to determine factors associated with OS following NAT in resected PDAC. Methods The PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL databases were systematically
-
State-level disparities in cervical cancer prevention and outcomes in the U.S.: a modeling study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-19 Fernando Alarid-Escudero, Valeria Gracia, Marina Wolf, Ran Zhao, Caleb W Easterly, Jane J Kim, Karen Canfell, Inge M C M de Kok, Ruanne V Barnabas, Shalini Kulasingam
Background Despite HPV vaccines’ availability for over a decade, coverage across the US varies. While some states have tried to increase HPV vaccination coverage, most model-based analyses focus on national impacts. We evaluated hypothetical changes in HPV vaccination coverage at the national and state levels for California, New York, and Texas using a mathematical model. Methods We developed a new
-
Obesity-Specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-19 Randall J Smith,Robert Zollo,Sukumar Kalvapudi,Yeshwanth Vedire,Akhil Goud Pachimatla,Cara Petrucci,Garrison Shaller,Deschana Washington,Vethanayagam Rr,Stephanie N Sass,Aravind Srinivasan,Eric Kannisto,Sawyer Bawek,Prantesh Jain,Spencer Rosario,Joseph Barbi,Sai Yendamuri
BACKGROUND Pre-clinical cancer studies ascribe promising anticancer properties to metformin. Yet, clinical findings vary, casting uncertainty on its therapeutic value for non-small cell lung cancer (NSCLC) patients. We hypothesized that metformin could benefit obese and overweight patients with NSCLC. METHODS We retrospectively analyzed two clinical cohorts and employed complementary mouse models to
-
RE: A population-based study of COVID-19 mortality risk in US cancer patients. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-14 Jason Semprini,Nosayaba Osazuwa-Peters
-
Cumulative Psychosocial and Health Disparities in US Adolescent Cigarette Smoking, 2002 to 2019 J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-13 Tyler G Erath, Fang Fang Chen, Michael DeSarno, Derek Devine, Adam M Leventhal, Warren K Bickel, Stephen T Higgins
Background Understanding disparities in adolescent cigarette smoking is important for effective prevention. Methods We investigated disparities in adolescent smoking based on cumulative reported psychosocial/health risk among respondents ages 12-17 years in the US National Survey of Drug Use and Health from 2002 to 2019. Multivariable regression estimated associations of cumulative risk, survey years
-
Impact of major depressive disorder on breast cancer outcomes: a national retrospective cohort study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-12 Maya Aboumrad, Corinne Joshu, Kala Visvanathan
Background Establishing whether women with major depressive disorder (MDD) who develop breast cancer (BC) have poor outcomes is key to optimizing care for this population. To address this, we examined associations between MDD and BC recurrence and mortality. Methods Using medical record data from the Veterans Affairs Healthcare System, we established a retrospective cohort of women with local or regional
-
Impact of knowledge of HPV positivity on cervical cytology performance in latin america J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-12 Arianis Tatiana Ramírez, David Mesher, Armando Baena, Yuli Salgado, Elena Kasamatsu, Carmen Cristaldo, Rodrigo Álvarez, Freddy David Rojas, Katherine Ramírez, Julieta Guyot, Odessa Henríquez, Hans González Palma, Bettsy Flores, Jhaquelin Peñaranda, María José Vero, Isabel Robinson, Mary Luz Rol, Guillermo Rodríguez, Carolina Terán, Annabelle Ferrera, María Alejandra Picconi, Alejandro Calderon, Laura
Background Cervical cytology is recommended by WHO as a triage option in HPV-based cervical cancer screening programmes. We assessed the performance of cytology to detect CIN3+ without and with knowledge of HPV positivity. Methods Women were screened with cytology and HPV across ESTAMPA study centres in Latin America. Screen-positives were referred to colposcopy with biopsy and treatment as needed
-
Supporting Evidence in Phase 2 Cancer Trial Protocols: A Content Analysis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-12 Selin Bicer, Angela Nelson, Katerina Carayannis, Jonathan Kimmelman
Background Phase 2 trials are instrumental for designing definitive efficacy trials or attaining accelerated approval. However, high attrition of drug candidates in phase 2 raises questions about their supporting evidence. Methods We developed a typology of supporting evidence for phase 2 cancer trials. We also devised a scheme for capturing elements that enable an assessment of the strength of such
-
Evaluating clinical utility of comprehensive genomic profiling-challenges and opportunities. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-08 Lisa M McShane,Lyndsay N Harris
-
Influence of endoxifen on mammographic density—results from the KARISMA trial J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-07 Mattias Hammarström, Marike Gabrielson, Jenny Bergqvist, Cecilia Lundholm, Alessio Crippa, Magnus Bäcklund, Yvonne Wengström, Signe Borgquist, Erik Eliasson, Mikael Eriksson, José Tapia, Kamila Czene, Per Hall
Purpose Monitoring metabolites of tamoxifen, such as endoxifen, has been suggested as a strategy to ascertain therapeutic effect of tamoxifen therapy but clinical guidelines are missing. Herein we aim to investigate the outcome of endoxifen concentrations of low dose tamoxifen, using change in mammographic breast density (MBD) as a proxy for therapy response. Material and Methods In the randomized
-
Expression of Concern: Delta-Like Ligand 4-Notch Blockade and Tumor Radiation Response. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-01
-
The Diverse Aspects of Uterine Serous Cancer: An NCI workshop on the status of and opportunities for advancement of research. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-05 Naveena B Janakiram,Megan A Clarke,Mihoko Kai,Tiffany A Wallace,Sandra Russo,Toby T Hecht,Elise C Kohn,Brandy Heckman-Stoddard
The marked increase in incidence and mortality in endometrial cancer over the last two decades is driven in part by rising rates of higher grade, more aggressive endometrial cancers with mutations in TP53, uterine serous cancers and their dedifferentiated component, uterine carcinosarcomas (collectively USC). USC rates have been increasing among all racial and ethnic groups, with higher rates of this
-
-
Enhancing Capacity for Primary Care Research in Cancer Survivorship: National Cancer Institute Meeting Report J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-02 Shawna V Hudson, Michelle A Mollica, Reed Crystal, Erin E Hahn, Denalee M O’Malley, Archana Radhakrishnan, Jennifer Klemp, Emily Tonorezos
Many components of long-term cancer follow-up and survivorship care are managed in the primary care context. Given the important role that primary care has in survivorship care, it is critical to ensure that teams in these settings are prepared to address long-term needs. Evidence-based strategies to deliver survivorship care in primary care settings in the US remain limited. The National Cancer Institute
-
What happens in the community? Broadening research on the impacts of mass incarceration. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-11-01 Andrea Knittel,Hazel B Nichols
-
Prediction of breast cancer risk for adolescents and young adults with Hodgkin lymphoma J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-10-30 Sander Roberti, Flora E van Leeuwen, Ibrahima Diallo, Florent de Vathaire, Michael Schaapveld, Wendy M Leisenring, Rebecca M Howell, Gregory T Armstrong, Chaya S Moskowitz, Susan A Smith, Berthe M P Aleman, Inge M Krul, Nicola S Russell, Ruth M Pfeiffer, Michael Hauptmann
Background While female survivors of Hodgkin lymphoma (HL) have an increased risk of breast cancer (BC), no BC risk prediction model is available. We developed such models incorporating mean radiation dose to the breast or breast quadrant-specific radiation doses. Methods Relative risks and age-specific incidence for BC and competing events (mortality or other subsequent cancer) were estimated from
-
Supplemental breast cancer screening after negative mammography in U.S. women with dense breasts J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-10-30 Victoria M Foster, Amy Trentham-Dietz, Natasha K Stout, Christoph I Lee, Laura E Ichikawa, Joanna Eavey, Louise Henderson, Diana L Miglioretti, Anna N A Tosteson, Erin A Bowles, Karla Kerlikowske, Brian L Sprague
The extent and determinants of supplemental screening among women with dense breasts are unclear. We evaluated a retrospective cohort of 498,855 women aged 40-74 years with heterogeneously or extremely dense breasts who obtained 1,176,251 negative screening mammography examinations during 2011-2019 in the United States. Overall, 2.8% and 0.3% of mammograms had supplemental ultrasound or MRI within
-
Cancer chemotherapy in pregnancy and adverse pediatric outcomes: a population-based cohort study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-10-30 Amy Metcalfe, Zoe F Cairncross, Carly A McMorris, Christine M Friedenreich, Gregg Nelson, Parveen Bhatti, Deshayne B Fell, Sarka Lisonkova, Khokan C Sikdar, Lorraine Shack, Joel G Ray
Background Administration of chemotherapy during pregnancy is often delayed, while preterm delivery is common. If in utero exposure to chemotherapy is associated with adverse pediatric outcomes, it is unknown whether that relationship is directly attributable to the chemotherapy or is mediated by preterm birth. Methods Cases were identified from Canadian cancer registries and administrative data in
-
Contribution of health insurance to racial and ethnic disparities in advanced stage diagnosis of 10 cancers J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-10-30 Parichoy Pal Choudhury, Helmneh M Sineshaw, Rachel A Freedman, Michael T Halpern, Leticia Nogueira, Ahmedin Jemal, Farhad Islami
For many cancer sites, it is unclear to what extent differences in health insurance coverage contribute to racial and ethnic disparities in stage III-IV diagnoses. Using the National Cancer Database (1,893,026 patients aged 18-64 years, diagnosed between 2013-2019), we investigated a potential mediating role of health insurance (privately insured vs uninsured) in explaining racial and ethnic disparities